What question did this study set out to answer?

This analysis aims to evaluate the efficacy of PPAR agonists on pruritus and quality of life in patients with primary biliary cholangitis.

March 25, 2026

Meta‐Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis

Puntos clave

This analysis aims to evaluate the efficacy of PPAR agonists on pruritus and quality of life in patients with primary biliary cholangitis.
Conducted a meta-analysis of clinical trials involving PPAR agonists
Focused on symptoms of pruritus and quality of life metrics
Included studies reporting itch-specific outcomes
PPAR agonists decreased the severity of pruritus in patients with moderate-to-severe symptoms
Improvement in itch-specific outcomes was consistent
Uncertainty remains regarding overall quality of life improvements

Resumen

PPAR agonists, notably bezafibrate and seladelpar, reduce pruritus severity in PBC patients with moderate-to-severe symptoms and consistently improve itch-specific outcomes. However, effects on global HRQoL remain uncertain. These findings underscore the incorporation of validated, symptom-focused endpoints in future PBC trials.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Adrielly Martins

Nidah S. Khakoo

C. Corpéchot

Journals

Alimentary Pharmacology & Therapeutics

Actions

Institutions

Inserm

Emory University

Sorbonne Université

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Meta‐Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis

Puntos clave

Resumen

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider